Misplaced Pages

This article may require cleanup to meet Misplaced Pages's quality standards. The specific problem is: Artificial insemination and ivf inline sources. Please help improve this article if you can. (December 2023) (Learn how and when to remove this message)

Part of a series on
LGBTQ topics
Lesbian Gay Bisexual Transgender Queer
Sexual orientation and gender Aromanticism Asexuality Gray asexuality Aceflux Demisexuality Fraysexuality Biology Bisexuality Pansexuality Demographics Environment Gender fluidity Gender identity Gender role Gender variance Homosexuality Intersex Non-heterosexual Non-binary gender Queer Queer heterosexuality Questioning Sexual identity Sex–gender distinction Trans man Trans woman Transgender Transsexual Two-spirit
History General Timeline Same-sex marriage Homosexuality Movements Gay liberation Same-sex unions Stonewall riots Identities Lesbian Gay men Bisexuality Transgender Intersex
Culture Business Coming out Community African-American Dyke March Events Awareness periods Largest events Gay village Media Films New queer cinema Periodicals LGBTQ culture in New York City Pride Pride Month Parade Queer art QPR and QPP Same-sex relationship Slang Polari Socialization Subcultures Symbols Flags Takatāpui Moe aikāne Tourism
Rights Adoption Civil union Decriminalization Gender self-identification Intersex human rights Legal recognition of non-binary gender Marriage Military service Parenting Rights by country or territory Right to sexuality Transgender rights Yogyakarta Principles
Health MSM and Blood donation restrictions / HIV LGBTQ medical organizations Reproduction Transgender health care Suicide Detransition
Social attitudes 2020s anti-LGBTQ movement in the United States Allonormativity Amatonormativity Cisnormativity Heteronormativity LGBTQ rights opposition Mixed-orientation marriage Media portrayal Religion and homosexuality / trans people Sexual diversity Stereotypes
Issues Acephobia Arophobia AIDS stigma Anti-LGBTQ rhetoric Grooming conspiracy theory Biphobia Bullying Censorship Closeted Outing Comphet Criminalization Domestic violence Erasure Straightwashing Bisexual Lesbian Trans Gay bashing Gayphobia Heteropatriarchy Heterosexism Homophobia Liberal Intersex discrimination Legality of conversion therapy Lesbophobia LGBTQ youth Suicide Vulnerability Migration Racism Sexualism Transphobia Non-binary people Trans men Trans women Violence Trans people
Academic fields and discourse Communism and LGBT rights Gender studies Lesbian feminism Lavender linguistics LGBTQ conservatism LGBT conservatism in the United States Queer anarchism Queer studies Queer theory Social construction of gender Socialism and LGBT rights Transfeminism Transgender studies Travesti
LGBTQ portal
v t e

Lesbian, gay, bisexual, and transgender people (LGBT community) people wishing to have children may use assisted reproductive technology. In recent decades, developmental biologists have been researching and developing techniques to facilitate same-sex reproduction.

The obvious approaches, subject to a growing amount of activity, are female sperm and male eggs. In 2004, by altering the function of a few genes involved with imprinting, other Japanese scientists combined two mouse eggs to produce daughter mice and in 2018 Chinese scientists created 29 female mice from two female mice mothers but were unable to produce viable offspring from two father mice. One of the possibilities is transforming skin stem cells into sperm and eggs.

Lack of access to assisted reproductive technologies is a form of healthcare inequality experienced by LGBT people.

Freezing eggs

LGBT women and trans men may choose to donate their eggs in order to reproduce by in-vitro fertilization. Trans men in particular may freeze their eggs before transitioning and choose to have a female surrogate carry their child while when the time comes, using their eggs and someone else's sperm. This allows them to avoid the potentially dysphoria-triggering experience of pregnancy, or cessation of HRT for collecting eggs at an older age.

Egg banking

Cryopreservation of oocytes (eggs) requires hormonal stimulation and oocyte retrieval, as for IVF treatment, after which the oocytes are vitrified. Vitrification of oocytes has been found to be more successful than slow freezing oocytes. The success of oocyte banking declines significantly with increasing reproductive age. Ovarian stimulation will increase transgender men's serum estradiol levels, and in response transvaginal ultrasound monitoring may be necessary, strategies to minimize estradiol elevations include the concomitant use of aromatase inhibitors during stimulation. There is no data on the success of ovarian stimulation in transgender men who previously had puberty halted with GnRH agonist, followed directly by testosterone administration. There is also no data comparing the number of oocytes retrieved or the live-birth rate after fertility preservation stratified by time off testosterone.

Ovarian tissue banking

A surgical procedure is required to collect tissue samples, if undergoing a hysterectomy and/or ovariectomy, one can choose to cryopreserve some tissue at the same time to avoid an additional surgical procedure. Ovarian tissue cryopreservation has been successful, but so far, there have been no pregnancies recorded after thawing and in-vitro maturation (IVM) of this tissue, successful pregnancies have only been recorded after auto-transplantation. This method has a very low success rate of blastocyst development as in one study of 83 transgender males, 2 out of the 208 mature oocytes were recovered from thawed ovarian tissue created "good-quality" blastocysts.

Freezing sperm

For the purposes of either in-vitro fertilization or artificial insemination, LGBT individuals may choose to preserve their eggs or sperm.

Trans women may have lower sperm quality before HRT, which may pose an issue for creating viable sperm samples to freeze.

Estrogens suppress testosterone levels and at high doses can markedly disrupt sex drive and function and fertility on their own. Moreover, disruption of gonadal function and fertility by estrogens may be permanent after extended exposure.

Nonsteroidal antiandrogens like bicalutamide may be an option for transgender women who wish to preserve sex drive, sexual function, and/or fertility, relative to antiandrogens that suppress testosterone levels and can greatly disrupt these functions such as cyproterone acetate and GnRH modulators.

Semen can be collected via masturbation, but there are alternatives for those who find masturbation or ejaculation distressing or may have erectile or ejaculatory dysfunction secondary to hypoandrogenism. Options for those with dysfunction include: penile vibratory stimulation and electroejaculation. For those who do not want to ejaculate or have oligospermia or azoospermia can pursue testicular sperm aspiration or microsurgical sperm extraction although they are more invasive. There are currently no studies evaluating the acceptability or success rates of the different options for sperm collection specifically in transgender women. Furthermore, for transgender women on estradiol and/or antiandrogens, it is unclear the length of time needed to be off hormonal treatment medication before normal spermatogenesis resumes (if it occurs at all), during which time testosterone production will resume and may cause unwanted masculinizing effects.

Storing and selecting sperm

Prospective LGBT parents may have pick sperm from a sperm bank to grow their baby. The sperm can come from one partner, either having been frozen before their transition, or being recent in the case of a partner having functioning male organs. Other times, it can come from private sperm donors. LGBT individuals must carefully consider where they get their donor sperm from. Individual state's laws vary, but many U.S. states have adopted a form of the Uniform Parentage Act (UPA). Most, but not all states transfer parental rights from anonymous sperm donors to the intended parents as long as the recipient is a married woman, and a physician is involved. Noncompliance with these laws can result in the failure to terminate sperm donor parental rights. There have been court cases where known sperm donors that privately donated directly were requested to pay child support. For example, of these laws, see California assisted reproductive laws. In Australia, there has been legal precedent that sperm donor involvement with the ensuing child's life does grant them parental rights (Masson v Parsons).

Alternative to direct private donation it is possible to purchase sperm from a sperm bank for personal use in fertility treatment. Sperm banks can vary widely, not only in terms of price, but of practice (i.e. who is allowed to donate sperm, how many times, etc.) and can offer a variety of services. Major U.S. sperm banks include Fairfax Cryobank, California Cyrobank, Cryos International, Seattle Sperm bank, and Xytex, and many others.

Artificial insemination

In order to accommodate for different gender identities and sexual orientations, a LGBT pregnancy from donated sperm can be done through artificial insemination. It is putting the donated sperm inside the body of the carrying womb (surrogate pregnancy or other).

Timing of these procedures are critical for successful fertilization, as the fertile window is the five days before ovulation, plus the day of and after ovulation. To increase the chance of success, the menstrual cycle is closely observed, often using ovulation kits, ultrasounds or blood tests, such as basal body temperature tests over, noting the color and texture of the vaginal mucus, and the softness of the nose of the cervix. To improve the success rate of artificial insemination, drugs to create a stimulated cycle may be used called ovarian stimulation (OS).

Intrauterine insemination (IUI)

Before ovulation there is a surge of luteinizing hormone (LH) which can be used to time an IUI procedure. Data suggest that IUI should be performed 1 day after the detection of the LH surge. Most clinics in the U.S. perform IUI in the morning after a positive ovulation predictor kit test (which detects LH in urine). An alternative to LH monitoring is ultrasound monitoring of ovarian follicle size followed by a trigger shot with exogenous human chorionic gonadotropin (hCG) which mimics the body's LH surge and triggers final follicular maturation and rupture (36–48 hours later). The trigger shot is typically administered when the dominant follicle reaches 18–20 mm. The recommended timing of IUI after hCG administration is 24–40 hours. IUI cycles stimulated with classical doses of FSH have a high rate of have a multiple pregnancy with rates ranging from 10 to 40%. A meta-analysis showed no difference between pregnancy outcomes between at-home LH monitoring and timed IUI.

IUI can be done without the use of medication. IUI is not recommended in cases where the gestating individuals have cervical atresia, cervicitis, endometritis or bilateral tubal obstruction or when the sperm donor has amenorrhea or severe oligospermia. Prior to IUI, the sperm is "washed" which is necessary to remove seminal plasma to avoid prostaglandin-induced uterine contractions. Insemination with unprocessed semen is also associated with pelvic infection.

Intrauterine insemination (IUI) involves the opening of the vagina using a speculum, then injecting washed sperm directly into the uterus with a catheter. Insemination in this way means that the sperm do not have to swim through the cervix which is coated with a mucus layer. This layer of mucus can slow down the passage of sperm and can result in many sperm perishing before they can enter the uterus. Donor sperm is sometimes tested for mucus penetration capabilities if it is to be used for ICI inseminations, for if the sperm's chances of passing through the cervix is low, IUI would provide a more efficient delivery of the sperm than ICI . IUI fertilization takes place naturally in the external part of the fallopian tubes in the same way that occurs following intercourse.

The benefit of double IUI has not been found in patients with undocumented infertility using donor sperm, such as lesbian and single women. Typically pregnancy success rates per IUI cycle is approximately 12.4%. According to a study from 2021, lesbian women undergoing IUI had a clinical pregnancy rate of 13.2% per cycle and 42.2% success rate given the average number of cycles at 3.6. IUI has been reported to be more effective than ICI but this has been contested with some citing no strong evidence to confirm a significant difference between the birth rates of the two procedures. It is speculated that IUI is more effective since IUI brings the sperm closer to the oocyte than ICI which might compensate for decreased sperm motility after freezing and thawing. IUI includes risk of endometritis, cramping, bleeding, and anaphylaxis (rarely). A systematic review and meta-analysis was not able to demonstrate that bed rest after intrauterine insemination effectively increases in pregnancy rate.

Intracervical insemination (ICI)

Very similar to IUI, Intracervical insemination (ICI) is the method of artificial insemination which most closely mimics the natural ejaculation of semen by the penis into the vagina during sexual intercourse. ICI is the simplest method of artificial insemination and may also be performed privately in the home instead of at a private practice. ICI is the process of introducing semen into the vagina at the entrance to the cervix, usually by means of a needleless syringe. Sperm used in ICI inseminations does not have to be 'washed' to remove seminal fluid so raw semen from a private donor may be used. Semen supplied by a sperm bank prepared for ICI or IUI use is also suitable for ICI. A retrospective cohort study showed that total motility and total motile count (TMC) after thawing were associated with ongoing pregnancy rate; with best ICI results at total motility of ≥20% and a total motile count (TMC) of ≥8 × 106 after thawing.

During ICI, air is expelled from a needleless syringe which is then filled with semen. A specially-designed syringe, wider and with a more rounded end, may be used for this purpose. Any further enclosed air is removed by gently pressing the plunger forward. The recipient lies on their back and the syringe is inserted into the vagina so that the tip is as close to the entrance to the cervix as possible. A vaginal speculum may be used for this purpose and a catheter may be attached to the tip of the syringe to ensure delivery of the semen as close to the entrance to the cervix as possible. The plunger is then slowly pushed forward and the semen in the syringe is gently emptied deep into the vagina. It is important that the syringe is emptied slowly for safety and for the best results, bearing in mind that the purpose of the procedure is the replicate as closely as possible a natural deposit of the semen in the vagina. The syringe (and catheter if used) may be left in place for several minutes before removal. Following insemination, fertile sperm will swim through the cervix into the uterus and from there to the fallopian tubes in a natural way as if the sperm had been deposited in the vagina through intercourse. A conception cap instead of a syringe can be used as well.

In-vitro fertilization

Some LGBT may opt for using in-vitro fertilization instead of artificial insemination to reproduce. A zygote is created in a lab with a donated egg and a donated sperm, both of which can come from different sources like sperm banks, egg banks or one partner. Then, the zygote is implanted in the uterus. The carrying uterus can be a surrogate (gay men or other infertile couples) or one partner (female or trans man).

Standard IVF

Standard IVF is the process by which the egg is removed from the ovaries and fertilized outside of the body, and then the pre-embryo is implanted into a uterus. There are many steps to ensure that this process works including ovary stimulation, egg collection, fertilization, and embryo transfer. To stimulate the ovaries to produce more eggs than usual, the person must take specific hormones prescribed by a doctor. Then, the eggs are collected using an ultrasound-guided aspiration needle. Once the eggs are outside the body, they are mixed with sperm in a culture dish in the hopes of fertilization. The sperm used can come from any sperm donor (either from a sperm bank, or a known donor like a partner). If a pre-embryo forms, it remains in the incubator for two to five days while it continues to grow and divide. At this stage, the pre-embryo is often genetically tested to ensure that it will develop into a healthy baby. If the embryo is deemed healthy, the next step is implantation. The embryos are transferred to the uterus which involves an ultrasound being used to guide a catheter through the cervix and into the uterine cavity.

Reciprocal IVF

Partner-assisted reproduction, or co-IVF is a method of family building that is used by couples who both possess female reproductive organs. The method uses in vitro fertilization (IVF), a method that means eggs are removed from the ovaries, fertilized in a laboratory, and then one or more of the resulting embryos are placed in the uterus to hopefully create a pregnancy. Reciprocal IVF differs from standard IVF in that two women are involved: the eggs are taken from one partner, and the other partner carries the pregnancy. In this way, the process is mechanically identical to IVF with egg donation. Using this process ensures that each partner is a biological mother of the child according to advocates, but in the strictest sense only one mother is the biological mother from a genetic standpoint and the other is a surrogate mother. However the practice has a symbolic weight greater than LGBT adoption, and may create a stronger bond between mother and child than adoption.

In a 2019 study, quality of infant–parent relationships was examined among egg donor families in comparison to in vitro fertilization families. Infants were between the ages of 6–18 months. Through use of the Parent Development Interview (PDI) and observational assessment, the study found few differences between family types on the representational level, yet significant differences between family types on the observational level. Egg donation mothers were less sensitive and structuring than IVF mothers, and egg donation infants were less emotionally responsive, and involving than IVF infants. The eggs are then fertilized with donor sperm to create embryos, one of which can then be transferred to the second person's uterus. In this way, one partner contributes the genetic material and the second partner contributes the maternal environment, allowing both partners to have a profound impact on the development of the fetus and child. The laws around parenthood when both partners do not contribute genetic material are complicated and vary by state, so it is imperative to do research before beginning the process.

Pregnancy

The LGBT parent(s) may choose a surrogate or their partner for pregnancy, depending on their fertility and personal values. There are many possible ways for an LGBT individual or couple to become pregnant, such as:

• Artificial insemination.
• Embryo from in-vitro fertilization implant.
• Natural sexual activity (in the case of fertile couples with matching sexual orientation, or otherwise with a surrogate).
• Uterine transplant (yet to be achieved practically for trans women, but has been achieved for cisgender women).

Surrogacy

Some gay or transsexual couples decide to have a surrogate pregnancy. A surrogate is a woman carrying an egg fertilized by sperm of one of the men. Some women become surrogates for money, others for humanitarian reasons or both. This allows one of the men to be the biological father while the other will be an adopted father.

Gay men who have become fathers using surrogacy have reported similar experiences to those as other couples who have used surrogacy, including their relationships both their child and their surrogate have.

Barrie and Tony Drewitt-Barlow from the United Kingdom became the first gay men in the country to father twins born through surrogacy in 1999.

Surrogacy is a process in which a woman carries and delivers a child for a couple or an individual. This can be an arrangement supported by a legal agreement where the surrogate may or may not be compensated. Surrogacy is the most common form of accessing parenthood because it is less complicated due to the biological connection made between parent and child. LGBTQ+ individuals may seek surrogacy when they are in need for someone else to serve as the gestational carrier of their biological child. Recently, traveling for couples outside of the US to seek surrogacy is rising. Usually these commercial services cater only white, wealthy parents-to-be. In some countries it is illegal to pay surrogates, but the debate is that unpaid surrogacy can take place.

Choosing who will be the biological parent can vary from couple to couple because couples get to decide where gametes can come from. Gametes can be purchased through commercial resources, arranged through an agreement from a genetic connection to both parents, or through a friend donation.

There is a long history of transnational surrogacy used by gay parents who seek surrogacy in India. They use gametes fertilized by one or both parents to inseminate local women who are employed through an agency. There is global criticism due to transparency around pay and the outcomes for the parties involved. Because of this surrogacy services in India are being recalled by gay parents because there is restricted access to pregnancy updates. Unable to communicate can create emotional distancing for gay parents and the pregnancy can be stressful for gay parents. Going through surrogate services can be a stressful journey because gay parents are caught up in between charts and graphs, instead of being able to have an emotional connection with the baby through the surrogate and the experiences they go through.

Transnational surrogacy can raise legal issues when the child is born. There is conflict about national legal rules on parentage and this complicates citizenship, which can often result in the child not having legal parents or citizenship in any country.

The World Profession Association for Transgender Health (WPATH) recommends that all transgender patients make decisions regarding their fertility before starting hormone therapy in their Standards of Care (2012) guidebook for medical professionals.

Transgender men

Pregnancy is possible for transgender men who retain a functioning vagina, ovaries, and a uterus. Testosterone does not inhibit one's ability to become pregnant and give birth, as it is not a sufficient method of contraception. While trans men can become pregnant while taking testosterone, it is advised to stop before attempting to become pregnant, as taking testosterone during pregnancy can lead to issues with fetal development. Many trans men who have become pregnant were able to do so within six months of stopping testosterone. Another study conducted in 2019 found that transgender male patients seeking oocyte retrieval for either oocyte cryopreservation, embryo cryopreservation, or IVF were able to undergo treatment 4 months after stopping testosterone treatment, on average. There have been no studies of transgender men attempting pregnancy after testosterone or on the health of offspring conceived from testosterone-exposed oocytes, so exact fertility rates are unknown. However, a 2020 study found that intended pregnancy rates among respondents of a self-administered survey who had ever used testosterone were comparable to those to those who had not - 38% and 45% respectively.

Masculinizing hormonal therapy in trans men will often lead to amenorrhea, but this amenorrhea is usually reversible and androgen therapy does not deplete primordial follicles nor affects the developmental capacity of the follicles. However, histologically hyperplasia of the ovarian cortex and stroma has been found. It has been debated if this is physiologically comparable to polycystic ovary syndrome. Ovariectomies lead to irreversible fertility termination (if the eggs are not stored), but doesn't preclude gestational pregnancy with ART. Hysterectomies will eliminate the option to gestate.

Trans men and transmasculine people who become pregnant are frequently referred to as "seahorse dads."

Transgender women

Transgender women with a fertile partner may choose to have children through natural sexual activity. Some transgender women have reported a lower sexual desire on hormonal treatment. It has been found that transgender patients undergoing feminizing hormonal therapy do have abnormal semen parameters. Sustained hormonal treatment eventually leads to hypo-spermatogenesis and ultimately azoospermia which will become irreversible at an unknown point in time. A 2015 study did demonstrate normal spermatogenesis in long term estrogen therapy patients. Surgical removal of testicles also leads to irreversible sterility. It is recommended for those pursuing these options and interested in preserving fertility to cryogenically store their sperm before starting their treatment.

Barriers to fertility care

Economic

Fertility treatment and preservation is expensive. The average IVF cycle can cost $12,000 to $17,000 (not including medication), with medication it can up to $25,000-$30,000 and price often comes down to one's insurance which might come with stipulations. The cost of IUI ranges from $500–4,000 per cycle. Cryopreservation of genetic material is also costly see table below and can vary greatly from place to place, state to state.

Another barrier is knowledge. These procedures are not well known and discussion of fertility preservation are uncommon. In a study of 133 transgender women 61% stated that no health care provider discussed sperm banking prior to their hormone therapy or surgery. In another study, 70 transgender males cited barriers such as the perceived cost of treatment (36%), need for discontinuation or delay of hormonal therapy (19%), and worsening gender dysphoria with treatment and pregnancy (11%).

Physical

Only 3% of transgender people take efforts to preserve their fertility in transition 51% of trans women express regrets for not preserving their fertility, and 97% of transgender adults believe it should be discussed before transition.

Testosterone therapy affects fertility, but many trans men who have become pregnant were able to do so within six months of stopping testosterone. Another study conducted in 2019 found that transgender male patients seeking oocyte retrieval for either oocyte cryopreservation, embryo cryopreservation, or IVF were able to undergo treatment 4 months after stopping testosterone treatment, on average. All patients experienced menses and normal AMH, FSH, and E₂ levels and antral follicle counts after coming off testosterone which allowed for successful oocyte retrieval. Although the long-term effects of androgen treatment on fertility is still widely unknown, oocyte retrieval does not appear to be affected. Future pregnancies can be achieved by oophyte banking, but the process may increase gender dysphoria or may not be accessible due to lack of insurance coverage. Testosterone therapy is not a sufficient method of contraception, and trans men may experience unintended pregnancy, especially if they miss doses.

Some studies report a higher incidence of polycystic ovary syndrome (PCOS) among transgender men prior to taking testosterone, the disease causes infertility and can make it harder for trans men to freeze eggs, though not all have not found the same association of trans men and PCOS. People with PCOS in general are also reportedly more likely to see themselves as "sexually undifferentiated" or "androgynous" and "less likely to identify with a female gender scheme."

Future technology

There is theoretical work being done on creating a zygote from two men which would enable both men to be biological fathers, but it is yet to be practically implemented.

There is theoretical potential for same sex reproduction using stem cells to derive gametes to produce biologically related children, but this has been contentious and has been considered to be "impossible". However, scientists have successfully created eggs from male mice to produce offspring with 2 biologically male genetic donors and have been optimistic that human application could come within the next 10 years.

For prepubertal transgender girls, testicular tissue cryopreservation (TTC) is currently the only fertility preservation option. An experimental surgical procedure to remove and cryopreserve testicular tissue for a later date when the spermatogonial stem cells can be matured into sperm. To date no spermatogenic recovery has been reported and TTC technologies enabling this are currently only being studied in animal models

There is theoretical work being done on creating a zygote from two women which would enable both women to be biological mothers, but it is yet to be practically implemented. Creating a sperm from an egg and using it to fertilize another egg may offer a solution to this issue, as could a process analogous to somatic cell nuclear transfer involving two eggs being fused together.

In 2004 and 2018 scientists were able to create mice with two mothers via egg fusion. Modification of genomic imprinting was necessary to create healthy bimaternal mice, while live bipaternal mice were created but were unhealthy likely due to genomic imprinting.

If created, a "female sperm" cell could fertilize an egg cell, a procedure that, among other potential applications, might enable female same-sex couples to produce a child who would be the biological offspring of their two mothers. It is also claimed that production of female sperm may stimulate a woman to be both the mother and father (similar to asexual reproduction) of an offspring produced by her own sperm. Many queries, both ethical and moral, arise over these arguments.

Uterine transplantation

Some trans women want to carry their own children through transgender pregnancy, which has its own set of issues to be overcome, because transgender women do not naturally have the anatomy needed for embryonic and fetal development. As of 2008, there were no successful cases of uterus transplantation concerning a transgender woman.

Another possibility for transgender women would come from a successful uterus transplant that can carry a pregnancy to term in a transgender women. There have been successful births with uterus transplantation in cis-women, but currently none in trans women as currently there have been no successful uterus transplants in transgender women. Theoretical problems arise in the sexual dimorphism of the human pelvis, drug regime risk (post-transplant immunosuppression and hormone therapy to sustain implantation and pregnancy), and risk of neovaginal anastomosis. The same studies that identified these risks also came to the conclusion that despite the considerations uterine transplant shouldn't be confined to cis-women, with one journal article unable to find any increase in theoretical procedural risk compared to cis-women. There is no expectation that trans women would give birth through the neo-vaginal canal.

As of 2019, in cisgender women, more than 42 uterine transplant procedures had been performed, with 12 live births resulting from the transplanted uteruses as of publication. The International Society of Uterine Transplantation (ISUTx) was established internationally in 2016, with 70 clinical doctors and scientists, and currently has 140 intercontinental delegates. Its goal is to, "through scientific innovations, advance medical care in the field of uterus transplantation."

In 2012, McGill University published the "Montreal Criteria for the Ethical Feasibility of Uterine Transplantation", a proposed set of criteria for carrying out uterine transplants, in Transplant International. Under these criteria, only a cisgender woman could ethically be considered a transplant recipient. The exclusion of trans women from candidacy may lack justification.

In addition, if trans women wish to conceive with a cisgender male partner, they face the same issues that cisgender gay couples have in creating a zygote.

See also

• Male pregnancy
• LGBT parenting
• Transgender pregnancy
• Female sperm
• Male egg

References

1. Quick D (9 December 2010). "Breakthrough raises possibility of genetic children for same-sex couples". Retrieved 26 July 2015.
2. ^ "Japanese scientists produce mice without using sperm". The Washington Post. Sarasota Herald-Tribune. April 22, 2004.
3. ^ Blakely R (2018-10-12). "No father necessary as mice are created with two mothers". The Times (in enhsbr un=0140-0460). Retrieved 2018-10-12.{{cite news}}: CS1 maint: unrecognized language (link)
4. ^ Li ZK, Wang LY, Wang LB, Feng GH, Yuan XW, Liu C, Xu K, Li YH, Wan HF, Zhang Y, Li YF, Li X, Li W, Zhou Q, Hu BY (November 2018). "Generation of Bimaternal and Bipaternal Mice from Hypomethylated Haploid ESCs with Imprinting Region Deletions". Cell Stem Cell. 23 (5): 665–676.e4. doi:10.1016/j.stem.2018.09.004. PMID 30318303.
5. ^ Murray I (2021). "Stem Cells and Same Sex Reproduction". Retrieved 26 July 2015.
6. Tam MW (August 2021). "Queering reproductive access: reproductive justice in assisted reproductive technologies". Reproductive Health. 18 (1): 164. doi:10.1186/s12978-021-01214-8. PMC 8327458. PMID 34340704.
7. Compton J (5 March 2019). "Transgender men, eager to have biological kids, are freezing their eggs". NBC News. Retrieved 2021-07-05.
8. ^ T'Sjoen, Guy; Van Caenegem, Eva; Wierckx, Katrien (December 2013). "Transgenderism and reproduction". Current Opinion in Endocrinology, Diabetes & Obesity. 20 (6): 575–579. doi:10.1097/01.med.0000436184.42554.b7. ISSN 1752-296X. PMID 24468761. S2CID 205398449.
9. Herrero, Leyre; Martínez, Mónica; Garcia-Velasco, Juan A. (August 2011). "Current status of human oocyte and embryo cryopreservation". Current Opinion in Obstetrics and Gynecology. 23 (4): 245–250. doi:10.1097/GCO.0b013e32834874e2. ISSN 1040-872X. PMID 21734500. S2CID 32837692.
10. ^ Jones, C. A.; Reiter, L.; Greenblatt, E. (2016-04-02). "Fertility preservation in transgender patients". International Journal of Transgenderism. 17 (2): 76–82. doi:10.1080/15532739.2016.1153992. ISSN 1553-2739. S2CID 58849546.
11. ^ Moravek, Molly B. (June 2019). "Fertility preservation options for transgender and gender-nonconforming individuals". Current Opinion in Obstetrics and Gynecology. 31 (3): 170–176. doi:10.1097/GCO.0000000000000537. ISSN 1040-872X. PMID 30870185. S2CID 78091839.
12. ^ Douglas, Christopher R.; Phillips, Destiny; Sokalska, Anna; Aghajanova, Lusine (2022-05-02). "Fertility Preservation for Transgender Males". Obstetrics & Gynecology. 139 (6): 1012–1017. doi:10.1097/aog.0000000000004751. ISSN 0029-7844. PMID 35675598. S2CID 249332982.
13. Donnez, J; Dolmans, MM; Demylle, D; Jadoul, P; Pirard, C; Squifflet, J; Martinez-Madrid, B; Van Langendonckt, A (October 2004). "Livebirth after orthotopic transplantation of cryopreserved ovarian tissue". The Lancet. 364 (9443): 1405–1410. doi:10.1016/s0140-6736(04)17222-x. ISSN 0140-6736. PMID 15488215. S2CID 21448970.
14. Li K, Rodriguez D, Gabrielsen JS, Centola GM, Tanrikut C (November 2018). "Sperm cryopreservation of transgender individuals: trends and findings in the past decade". Andrology. 6 (6): 860–864. doi:10.1111/andr.12527. PMC 6301129. PMID 30094956.
15. Jones CA, Reiter L, Greenblatt E (2016). "Fertility preservation in transgender patients". International Journal of Transgenderism. 17 (2): 76–82. doi:10.1080/15532739.2016.1153992. ISSN 1553-2739. S2CID 58849546. Traditionally, patients have been advised to cryopreserve sperm prior to starting cross-sex hormone therapy as there is a potential for a decline in sperm motility with high-dose estrogen therapy over time (Lubbert et al., 1992). However, this decline in fertility due to estrogen therapy is controversial due to limited studies.
16. Payne AH, Hardy MP (28 October 2007). The Leydig Cell in Health and Disease. Springer Science & Business Media. pp. 422–431. ISBN 978-1-59745-453-7. Estrogens are highly efficient inhibitors of the hypothalamic-hypophyseal-testicular axis (212–214). Aside from their negative feedback action at the level of the hypothalamus and pituitary, direct inhibitory effects on the testis are likely (215,216). The histology of the testes showed disorganization of the seminiferous tubules, vacuolization and absence of lumen, and compartmentalization of spermatogenesis.
17. ^ Salam MA (2003). Principles & Practice of Urology: A Comprehensive Text. Universal-Publishers. pp. 684–. ISBN 978-1-58112-412-5. Estrogens act primarily through negative feedback at the hypothalamic-pituitary level to reduce LH secretion and testicular androgen synthesis. Interestingly, if the treatment with estrogens is discontinued after 3 yr. of uninterrupted exposure, serum testosterone may remain at castration levels for up to another 3 yr. This prolonged suppression is thought to result from a direct effect of estrogens on the Leydig cells.
18. ^ Cox RL, Crawford ED (December 1995). "Estrogens in the treatment of prostate cancer". The Journal of Urology. 154 (6): 1991–8. doi:10.1016/S0022-5347(01)66670-9. PMID 7500443.
19. Adeleye AJ, Reid G, Kao CN, Mok-Lin E, Smith JF (February 2019). "Semen Parameters Among Transgender Women With a History of Hormonal Treatment". Urology. 124: 136–141. doi:10.1016/j.urology.2018.10.005. PMID 30312673. S2CID 52973277.
20. Gao Y, Maurer T, Mirmirani P (August 2018). "Understanding and Addressing Hair Disorders in Transgender Individuals". American Journal of Clinical Dermatology. 19 (4): 517–527. doi:10.1007/s40257-018-0343-z. PMID 29352423. S2CID 6467968. Non-steroidal antiandrogens include flutamide, nilutamide, and bicalutamide, which do not lower androgen levels and may be favorable for individuals who want to preserve sex drive and fertility .
21. Iversen P, Melezinek I, Schmidt A (January 2001). "Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function". BJU International. 87 (1): 47–56. doi:10.1046/j.1464-410x.2001.00988.x. PMID 11121992. S2CID 28215804.
22. ^ Luetkemeyer, Lisa; West, Kimela (2015). "Paternity Law: Sperm Donors, Surrogate Mothers and Child Custody". Missouri Medicine. 112 (3): 162–165. ISSN 0026-6620. PMC 6170122. PMID 26168582.
23. Narayan, Chandrika (2014-01-23). "Kansas court says sperm donor must pay child support". CNN. Retrieved 2023-11-16.
24. "Court voids ruling that sperm donor must pay child support". AP News. 2021-06-16. Retrieved 2023-11-16.
25. "Do Sperm Donors Pay Child Support?". Boyd Law. 2018-07-16. Retrieved 2023-11-16.
26. Seery, Cassandra (2019-06-19). "Can a sperm donor be a legal parent? In landmark decision, the High Court says yes". The Conversation. Retrieved 2023-11-16.
27. ^ Potapragada, Nivedita R.; Babayev, Elnur; Strom, Danielle; Beestrum, Molly; Schauer, Jacob M.; Jungheim, Emily S. (2023-06-07). "Intrauterine Insemination After Human Chorionic Gonadotropin Trigger or Luteinizing Hormone Surge". Obstetrics & Gynecology. 142 (1): 61–70. doi:10.1097/aog.0000000000005222. ISSN 0029-7844. PMID 37290111. S2CID 259118454.
28. ^ "Calculating Your Monthly Fertility Window". www.hopkinsmedicine.org. 2022-03-10. Retrieved 2023-12-04.
29. ^ The ESHRE Capri Workshop Group (2009-01-16). "Intrauterine insemination". Human Reproduction Update. 15 (3): 265–277. doi:10.1093/humupd/dmp003. ISSN 1355-4786. PMID 19240042.
30. "Intrauterine insemination (IUI) - Mayo Clinic". www.mayoclinic.org. Retrieved 2023-11-26.
31. "IUI (Intrauterine Insemination): What It Is & What To Expect". Cleveland Clinic. Retrieved 2023-11-26.
32. Monseur, Brent C.; Franasiak, Jason M.; Sun, Li; Scott, Richard T.; Kaser, Daniel J. (2019-10-01). "Double intrauterine insemination (IUI) of no benefit over single IUI among lesbian and single women seeking to conceive". Journal of Assisted Reproduction and Genetics. 36 (10): 2095–2101. doi:10.1007/s10815-019-01561-3. ISSN 1573-7330. PMC 6823402. PMID 31410635.
33. ^ Johal, Jasmyn K.; Gardner, Rebecca M.; Vaughn, Sara J.; Jaswa, Eleni G.; Hedlin, Haley; Aghajanova, Lusine (2021-04-28). "Pregnancy success rates for lesbian women undergoing intrauterine insemination". F&S Reports. 2 (3): 275–281. doi:10.1016/j.xfre.2021.04.007. ISSN 2666-3341. PMC 8441558. PMID 34553151.
34. ^ Chen, Xiao-Jun; Wu, Li-Ping; Lan, Hai-Lian; Zhang, Li; Zhu, Yi-Min (2012). "Clinical Variables Affecting The Pregnancy Rate of Intracervical Insemination Using Cryopreserved Donor Spermatozoa: A Retrospective Study in China". International Journal of Fertility & Sterility. 6 (3): 179–184. ISSN 2008-076X. PMC 3850307. PMID 24520436.
35. ^ Kop, P A L; van Wely, M; Nap, A; Soufan, A T; de Melker, A A; Mol, B W J; Bernardus, R E; De Brucker, M; Janssens, P M W; Pieters, J J P M; Repping, S; van der Veen, F; Mochtar, M H (2022-04-23). "Intracervical insemination versus intrauterine insemination with cryopreserved donor sperm in the natural cycle: a randomized controlled trial". Human Reproduction. 37 (6): 1175–1182. doi:10.1093/humrep/deac071. ISSN 0268-1161. PMC 9789751. PMID 35459949.
36. Kop, Petronella AL; Mochtar, Monique H; O'Brien, Paul A; Van der Veen, Fulco; van Wely, Madelon (2018-01-25). "Intrauterine insemination versus intracervical insemination in donor sperm treatment". Cochrane Database of Systematic Reviews. 2018 (2): CD000317. doi:10.1002/14651858.cd000317.pub4. ISSN 1465-1858. PMC 6491301. PMID 29368795.
37. Cordary, D.; Braconier, A.; Guillet-May, F.; Morel, O.; Agopiantz, M.; Callec, R. (2017-12-01). "Immobilization versus immediate mobilization after intrauterine insemination: A systematic review and meta-analysis". Journal of Gynecology Obstetrics and Human Reproduction. 46 (10): 747–751. doi:10.1016/j.jogoh.2017.09.005. ISSN 2468-7847. PMID 28964965.
38. "Intracervical insemination (ICI) -". 2022-10-08. Retrieved 2023-11-28.
39. Kop, Petronella; van Wely, Madelon; de Melker, Annemieke; van der Veen, Fulco; Mochtar, Monique (2022-02-04). "Donor sperm treatment: the role of semen parameters in intracervical insemination, a retrospective cohort study". Human Fertility. 26 (5): 964–970. doi:10.1080/14647273.2022.2032407. ISSN 1464-7273. PMID 35114884. S2CID 246529633.
40. ^ MarketingInsights. "Standard IVF". The IVF Center | Assisted Reproduction and Endocrinology. Retrieved 2023-12-04.
41. Gilmour P (6 June 2018). "Shared motherhood: The amazing way lesbian couples are having babies". Cosmopolitan. Retrieved 21 March 2018.
42. Klatsky P (22 June 2017). "Co-Maternity And Reciprocal IVF: Empowering lesbian parents with options". Huffington Post. Retrieved 21 March 2018.
43. Marina S, Marina D, Marina F, Fosas N, Galiana N, Jové I (April 2010). "Sharing motherhood: biological lesbian co-mothers, a new IVF indication". Human Reproduction. 25 (4): 938–41. doi:10.1093/humrep/deq008. PMID 20145005.
44. Schenker JG (2011). Ethical dilemmas in assisted reproductive technologies. Berlin: De Gruyter. ISBN 978-3-11-024021-4. OCLC 763156926.
45. ^ Imrie S, Jadva V, Fishel S, Golombok S (July 2019). "Families Created by Egg Donation: Parent-Child Relationship Quality in Infancy". Child Development. 90 (4): 1333–1349. doi:10.1111/cdev.13124. PMC 6640047. PMID 30015989.
46. ^ "Reciprocal IVF | UCSF Center for Reproductive Health". UCSF. Retrieved 2023-12-04.
47. "For Gay Men: Becoming a Parent through Surrogacy". Internet Health Resources. Retrieved 26 July 2015.
48. Blake L, Carone N, Slutsky J, Raffanello E, Ehrhardt AA, Golombok S (November 2016). "Gay father surrogacy families: relationships with surrogates and egg donors and parental disclosure of children's origins". Fertility and Sterility. 106 (6): 1503–1509. doi:10.1016/j.fertnstert.2016.08.013. PMC 5090043. PMID 27565261.
49. Woodward W (13 December 1999). "Gay couple celebrate birth of twins Aspen and Saffron". The Guardian.
50. Wakefield L (13 December 2021). "Britain's 'first gay dads' expecting triplets with daughter's ex-boyfriend". PinkNews.
51. ^ Obedin-Maliver, Juno; Makadon, Harvey J (March 2016). "Transgender men and pregnancy". Obstetric Medicine. 9 (1): 4–8. doi:10.1177/1753495X15612658. ISSN 1753-495X. PMC 4790470. PMID 27030799.
52. ^ Leung, Angela; Sakkas, Denny; Pang, Samuel; Thornton, Kim; Resetkova, Nina (2019-11-01). "Assisted reproductive technology outcomes in female-to-male transgender patients compared with cisgender patients: a new frontier in reproductive medicine". Fertility and Sterility. 112 (5): 858–865. doi:10.1016/j.fertnstert.2019.07.014. ISSN 0015-0282. PMID 31594633.
53. Light, Alexis; Wang, Lin-Fan; Zeymo, Alexander; Gomez-Lobo, Veronica (2018-10-01). "Family planning and contraception use in transgender men". Contraception. 98 (4): 266–269. doi:10.1016/j.contraception.2018.06.006. ISSN 0010-7824. PMID 29944875. S2CID 49434157.
54. "Testosterone and pregnancy". nhs.uk. 2022-05-31. Retrieved 2024-01-05.
55. Berger, Anthony P.; Potter, Elizabeth M.; Shutters, Christina M.; Imborek, Katherine L. (2015-09-01). "Pregnant transmen and barriers to high quality healthcare". Proceedings in Obstetrics and Gynecology. 5 (2): 1–12. doi:10.17077/2154-4751.1285. ISSN 2154-4751.
56. Moseson, Heidi; Fix, Laura; Stoeffler, Ari; Lunn, Mitchell R.; Flentje, Annesa; Lubensky, Micah E.; Capriotti, Matthew R.; Ragosta, Sachiko; Forsberg, Hannah; Obedin-Maliver, Juno (17 Nov 2020). "Pregnancy intentions and outcomes among transgender, nonbinary, and gender-expansive people assigned female or intersex at birth in the United States: Results from a national, quantitative survey". International Journal of Transgender Health. 22 (1–2): 30–41. doi:10.1080/26895269.2020.1841058. PMC 8040680 – via Taylor & Francis Online.
57. Wesp, Linda; Demidont, A. C.; Scott, Jelinek; Goldstein, Zil (2022), "Gender-Affirming Medical Care for Transgender and Gender Nonbinary Patients", Sexual and Reproductive Health, Cham: Springer International Publishing, pp. 287–308, doi:10.1007/978-3-030-94632-6_14, ISBN 978-3-030-94631-9, retrieved 2024-01-05
58. "I'm a transgender dad. Here's what people get wrong about me". TODAY.com. 2023-03-31. Retrieved 2024-01-03.
59. Wierckx, Katrien; Van Caenegem, Eva; Schreiner, Thomas; Haraldsen, Ira; Fisher, Alessandra; Toye, Kaatje; Kaufman, Jean Marc; T'Sjoen, Guy (August 2014). "Cross-Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short-Time Follow-Up: Results from the European Network for the Investigation of Gender Incongruence". The Journal of Sexual Medicine. 11 (8): 1999–2011. doi:10.1111/jsm.12571. hdl:2158/1060207. ISSN 1743-6095. PMID 24828032.
60. Li, Kai; Rodriguez, Dayron; Gabrielsen, J. Scott; Centola, Grace M.; Tanrikut, Cigdem (November 2018). "Sperm Cryopreservation of Transgender Individuals: Trends and Findings in the Past Decade". Andrology. 6 (6): 860–864. doi:10.1111/andr.12527. ISSN 2047-2919. PMC 6301129. PMID 30094956.
61. Adeleye, Amanda J.; Reid, Garrett; Kao, Chia-Ning; Mok-Lin, Evelyn; Smith, James F. (2019-02-01). "Semen Parameters Among Transgender Women With a History of Hormonal Treatment". Urology. 124: 136–141. doi:10.1016/j.urology.2018.10.005. ISSN 0090-4295. PMID 30312673. S2CID 52973277.
62. Rowlands, Sam; Amy, Jean-Jacques (2018-01-02). "Preserving the reproductive potential of transgender and intersex people". The European Journal of Contraception & Reproductive Health Care. 23 (1): 58–63. doi:10.1080/13625187.2017.1422240. ISSN 1362-5187. PMID 29323576. S2CID 3784307.
63. ^ Amir, Hadar; Yaish, Iris; Oren, Asaf; Groutz, Asnat; Greenman, Yona; Azem, Foad (2020-09-01). "Fertility preservation rates among transgender women compared with transgender men receiving comprehensive fertility counselling". Reproductive BioMedicine Online. 41 (3): 546–554. doi:10.1016/j.rbmo.2020.05.003. ISSN 1472-6483. PMID 32651108. S2CID 219435735.
64. Klein, Amy (2020-04-18). "I.V.F. is Expensive. Here's How to Bring Down the Cost". The New York Times. ISSN 0362-4331. Retrieved 2023-12-04.
65. ^ "How Much Does IVF Cost?". Forbes Health. 2021-09-28. Retrieved 2023-12-04.
66. Snider, Susannah (September 29, 2020). ""How Much Does IUI Cost and How Do I Pay for It?"". U.S. News.
67. ^ "Paying For Treatments". Alliance for Fertility Preservation. Retrieved 2023-12-04.
68. PFCLA. "Cost of Egg & Embryo Freezing in the U.S. | PFCLA". www.pfcla.com. Retrieved 2023-12-04.
69. "How Much Does It Cost To Freeze Sperm?". Forbes Health. 2022-12-01. Retrieved 2023-12-04.
70. "Sperm Banking". www.hopkinsmedicine.org. 2021-11-02. Retrieved 2023-12-04.
71. Asafu-Adjei, Denise; Caputo, Joseph M.; Bockting, Walter O.; Diah, Jonathan; Alukal, Joseph; Stahl, Peter J. (April 2020). "MP26-16 Mismatch Between Attitudes Towards Fertility and Clinical Care for Fertility Preservation in Transgender Women: Data From Project Affirm". Journal of Urology. 203 (Supplement 4). doi:10.1097/ju.0000000000000865.016. ISSN 0022-5347.
72. Nahata L, Tishelman AC, Caltabellotta NM, Quinn GP (July 2017). "Low Fertility Preservation Utilization Among Transgender Youth". The Journal of Adolescent Health. 61 (1): 40–44. doi:10.1016/j.jadohealth.2016.12.012. PMID 28161526.
73. "IJ TRANSGENDER - The Desire to have Children and the Preservation of Fertility in Transsexual Women: A Survey". 2021-06-30. Archived from the original on 2021-06-30. Retrieved 2022-02-23.
74. "Many transgender individuals consider their fertility important, survey shows". www.endocrine.org. Retrieved 2022-02-23.
75. ^ Berger AP, Potter EM, Shutters CM, Imborek KL (2015). "Pregnant transmen and barriers to high quality healthcare". Proceedings in Obstetrics and Gynecology. 5 (2): 1–12. doi:10.17077/2154-4751.1285.
76. ^ Leung A, Sakkas D, Pang S, Thornton K, Resetkova N (November 2019). "Assisted reproductive technology outcomes in female-to-male transgender patients compared with cisgender patients: a new frontier in reproductive medicine". Fertility and Sterility. 112 (5): 858–865. doi:10.1016/j.fertnstert.2019.07.014. PMID 31594633. S2CID 203983887.
77. Light A, Wang LF, Zeymo A, Gomez-Lobo V (October 2018). "Family planning and contraception use in transgender men". Contraception. 98 (4): 266–269. doi:10.1016/j.contraception.2018.06.006. PMID 29944875. S2CID 49434157.
78. Baba T, Endo T, Honnma H, Kitajima Y, Hayashi T, Ikeda H, Masumori N, Kamiya H, Moriwaka O, Saito T (April 2007). "Association between polycystic ovary syndrome and female-to-male transsexuality". Human Reproduction. 22 (4): 1011–1016. CiteSeerX 10.1.1.519.7356. doi:10.1093/humrep/del474. PMID 17166864.
79. Becerra-Fernández A, Pérez-López G, Román MM, Martín-Lazaro JF, Lucio Pérez MJ, Asenjo Araque N, Rodríguez-Molina JM, Berrocal Sertucha MC, Aguilar Vilas MV (August 2014). "Prevalence of hyperandrogenism and polycystic ovary syndrome in female to male transsexuals" [Prevalence of hyperandrogenism and polycystic ovary syndrome in female to male transsexuals]. Endocrinologia y Nutricion (in Spanish). 61 (7): 351–358. doi:10.1016/j.endonu.2014.01.010. PMID 24680383. S2CID 162299777.
80. Balen AH, Schachter ME, Montgomery D, Reid RW, Jacobs HS (March 1993). "Polycystic ovaries are a common finding in untreated female to male transsexuals". Clinical Endocrinology. 38 (3): 325–329. doi:10.1111/j.1365-2265.1993.tb01013.x. PMID 8458105. S2CID 72741370.
81. "What are the symptoms of PCOS?". Eunice Kennedy Shriver National Institute of Child Health and Human Development. 29 September 2022.
82. ^ Cesta CE, Månsson M, Palm C, Lichtenstein P, Iliadou AN, Landén M (November 2016). "Polycystic ovary syndrome and psychiatric disorders: Co-morbidity and heritability in a nationwide Swedish cohort". Psychoneuroendocrinology. 73: 196–203. doi:10.1016/j.psyneuen.2016.08.005. hdl:10616/45608. PMID 27513883. S2CID 207460386.
83. Kowalczyk R, Skrzypulec V, Lew-Starowicz Z, Nowosielski K, Grabski B, Merk W (June 2012). "Psychological gender of patients with polycystic ovary syndrome". Acta Obstetricia et Gynecologica Scandinavica. 91 (6): 710–714. doi:10.1111/j.1600-0412.2012.01408.x. PMID 22443151. S2CID 25055401.
84. ^ Ringler G (18 March 2015). "Get Ready for Embryos From Two Men or Two Women". Retrieved 4 July 2021.
85. ^ Segers, Seppe; Mertes, Heidi; Pennings, Guido; de Wert, Guido; Dondorp, Wybo (2017-01-25). "Using stem cell-derived gametes for same-sex reproduction: an alternative scenario". Journal of Medical Ethics. 43 (10): 688–691. doi:10.1136/medethics-2016-103863. ISSN 0306-6800. PMID 28122990. S2CID 35387886.
86. Adashi, Eli Y.; Cohen, I. Glenn (2020-11-15). "Assisted Same-Sex Reproduction: The Promise of Haploid Stem Cells?". Stem Cells and Development. 29 (22): 1417–1419. doi:10.1089/scd.2020.0146. ISSN 1547-3287. PMID 32967574. S2CID 221888407.
87. Devlin, Hannah; correspondent, Hannah Devlin Science (2023-03-08). "Scientists create mice with two fathers after making eggs from male cells". The Guardian. ISSN 0261-3077. Retrieved 2023-11-30. {{cite news}}: |last2= has generic name (help)
88. Hunt, Katie (2023-03-24). "Scientists create mice from two dads after making eggs from skin cells". CNN. Retrieved 2023-11-30.
89. Foster H (2013-08-16). "Mommy 1 and Mommy 2: Could science end the age of Mom and Dad?". Science in the News. Retrieved 2021-07-05.
90. "Early-stage sperm cells created". Newcastle University. 2007-04-13. Archived from the original on 2013-11-09.
91. Highfield R (2007-04-14). "Women may be able to grow own sperm". London: Daily Telegraph. Retrieved 2010-05-02.
92. Connor S (2007-04-13). "The prospect of all-female conception". The Independent. London. Archived from the original on 2011-01-06. Retrieved 2010-05-02.
93. "Bone stem cells turned into primitive sperm cells". New Scientist. 2007-04-13.
94. Leith W (2008-04-10). "Pregnant men: hard to stomach?". Telegraph. London.
95. ^ Jones, BP; Williams, NJ; Saso, S; Thum, M-Y; Quiroga, I; Yazbek, J; Wilkinson, S; Ghaem-Maghami, S; Thomas, P; Smith, JR (January 2019). "Uterine transplantation in transgender women". BJOG. 126 (2): 152–156. doi:10.1111/1471-0528.15438. ISSN 1470-0328. PMC 6492192. PMID 30125449.
96. ^ Richards, Elliott G.; Ferrando, Cecile A.; Farrell, Ruth M.; Flyckt, Rebecca L. (March 2023). "A "first" on the horizon: the expansion of uterus transplantation to transgender women". Fertility and Sterility. 119 (3): 390–391. doi:10.1016/j.fertnstert.2023.01.017. ISSN 0015-0282. PMID 36669554. S2CID 256057677.
97. ^ Mookerjee, Vikram G.; Kwan, Daniel (2019-04-25). "Uterus transplantation as a fertility option in transgender healthcare". International Journal of Transgenderism. 21 (2): 122–124. doi:10.1080/15532739.2019.1599764. ISSN 2689-5269. PMC 7430417. PMID 33005906.
98. Balayla, Jacques; Pounds, Pauline; Lasry, Ariane; Volodarsky-Perel, Alexander; Gil, Yaron (May 2021). "The Montreal Criteria and uterine transplants in transgender women". Bioethics. 35 (4): 326–330. doi:10.1111/bioe.12832. ISSN 0269-9702. PMID 33550647. S2CID 231862917.
99. Jones BP, Williams NJ, Saso S, Thum MY, Quiroga I, Yazbek J, Wilkinson S, Ghaem-Maghami S, Thomas P, Smith JR (January 2019). "Uterine transplantation in transgender women". BJOG. 126 (2): 152–156. doi:10.1111/1471-0528.15438. PMC 6492192. PMID 30125449.
100. "History of ISUTx". International Society for Uterus Transplantation (ISUTx). Archived from the original on 2021-11-23. Retrieved 2021-07-26.
101. "About - 'Vision'". International Society for Uterus Transplantation (ISUTx). Archived from the original on 2021-11-23. Retrieved 2021-07-26.
102. Lefkowitz A, Edwards M, Balayla J (April 2012). "The Montreal Criteria for the Ethical Feasibility of Uterine Transplantation". Transplant International. 25 (4): 439–47. doi:10.1111/j.1432-2277.2012.01438.x. PMID 22356169. S2CID 39516819.
103. Lefkowitz A, Edwards M, Balayla J (October 2013). "Ethical considerations in the era of the uterine transplant: an update of the Montreal Criteria for the Ethical Feasibility of Uterine Transplantation". Fertility and Sterility. 100 (4): 924–6. doi:10.1016/j.fertnstert.2013.05.026. PMID 23768985. However, it certainly bears mentioning that there does not seem to be a prima facie ethical reason to reject the idea of performing uterine transplant on a male or trans patient. A patient assigned male at birth wishing to gestate a child does not have a lesser claim to that desire than anyone else. The principle of autonomy is not sex-specific. This right is not absolute, but it is not the business of medicine to decide what is unreasonable to request for a person of sound mind, except as it relates to medical and surgical risk, as well as to distribution of resources. A male who identifies as a woman, for example, arguably has UFI, no functionally different from a woman who is born female with UFI. Irrespective of the surgical challenges involved, such a person's right to self-governance of her reproductive potential ought to be equal to her genetically female peers and should be respected.

External links

• Timeline of same-sex procreation scientific developments

• Assisted reproductive technology
• Fertility medicine
• LGBTQ parenting
• Human reproduction
• LGBTQ and health care